PCSK9 and breast carcinoma: A growing amount of evidence has manifested that PCSK9 show a promising advantage to cancer progression as well as poor clinical prognosis in several malignant tumors, such as melanoma (14), non-small cell lung cancer (NSCLC) (15), breast cancer (16), and hepatocellular carcinoma(HCC) (20).